Cyclerion Therapeutics (CYCN) Receivables (2020 - 2025)

Cyclerion Therapeutics has reported Receivables for 6 years, with the latest figure at $1.0 million in Q4 2025.

• On a quarterly basis, Receivables rose 79.86% year-over-year to $1.0 million in Q4 2025; TTM through Dec 2025 was $1.0 million, a 79.86% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 79.86% from the prior year.
• Receivables was $1.0 million for Q4 2025 at Cyclerion Therapeutics, up from $100000.0 in the prior quarter.
• The five-year high for Receivables was $1.0 million in Q4 2025, with the low at $44000.0 in Q3 2024.
• Average Receivables over 5 years is $302846.2, with a median of $227000.0 recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Receivables tumbled 57.71% in 2023, then soared 127.27% in 2025.
• Over 5 years, Receivables stood at $100000.0 in 2021, then decreased by 4.0% to $96000.0 in 2022, then changed by 0.0% to $96000.0 in 2023, then jumped by 479.17% to $556000.0 in 2024, then surged by 79.86% to $1.0 million in 2025.
• The last three Receivables figures came in at $1.0 million (Q4 2025), $100000.0 (Q3 2025), and $525000.0 (Q2 2025), per Business Quant data.